Body composition and survival in the early clinical trials setting von Veasey Rodrigues, H, Baracos, V.E, Wheler, J.J, Parsons, H.A, Hong, D.S, Naing, A, Fu, S, Falchoock, G, Tsimberidou, A.M, Piha-Paul, S, Chisholm, G, Kurzrock, R

Volltext

18 Pursuing Molecular Stratification in Phase I Trials von Kurzrock, R, Tsimberidou, A.M, Hong, D.S, Wheler, J.J, Falchook, G.S, Fu, S, Naing, A, Janku, F, Wen, S, Berry, D

Volltext

457 Actionable Mutations in Circulating Tumor DNA and Response to Target-based Therapies von Janku, F, Angenendt, P, Fu, S, Falchook, G.S, Hong, D.S, Naing, A, Tsimberidou, A.M, Wheler, J.J, Diehl, F, Kurzrock, R

Volltext

169 BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (Idylla™) von Janku, F, Huang, H.J, Claes, B, Falchook, G.S, Naing, A, Piha-Paul, S, Tsimberidou, A.M, Zinner, R.G, Karp, D.D, Fu, S, Subbiah, V, Hong, D.S, Wheler, J.J, Luthra, R.G, Patel, S.P, Kopetz, E.S, Sablon, E, Maertens, G, Kurzrock, R, Meric-Bernstam, F

Volltext

246 Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 Patients and Experience with Early-phase Protocols with PI3K/AKT/mTOR Inhibitors von Janku, F, Hong, D.S, Fu, S, Piha-Paul, S.A, Naing, A, Falchook, G.S, Tsimberidou, A.M, Stepanek, V.M, Wheler, J.J, Kurzrock, R

Volltext

Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer von Falchook, G.S., Moulder, S.L., Wheler, J.J., Jiang, Y., Bastida, C.C., Kurzrock, R.

Volltext

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs von Naing, A., Veasey-Rodrigues, H., Hong, D.S., Fu, S., Falchook, G.S., Wheler, J.J., Tsimberidou, A.M., Wen, S., Fessahaye, S.N., Golden, E.C., Aaron, J., Ewer, M.S., Kurzrock, R.

Volltext

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy von Wheler, J.J., Falchook, G.S., Tsimberidou, A.M., Hong, D.S., Naing, A., Piha-Paul, S.A., Chen, S.S., Fu, S., Stephen, B., Fok, J.Y., Janku, F., Kurzrock, R.

Volltext

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience von Wheler, J.J., Tsimberidou, A.M., Hong, D.S., Naing, A., Falchook, G.S., Fu, S., Moulder, S., Stephen, B., Wen, S., Kurzrock, R.

Volltext

PP65 PIK3CA mutations in patients with advanced cancers treated in a phase I clinic von Janku, F, Hong, D.S, Tsimberidou, A.M, Naing, A, Falchook, G.S, Wheler, J.J, Moulder, S.L, Kurzrock, R

Volltext

MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction von Janku, F., Huang, H.J., Fujii, T., Shelton, D.N., Madwani, K., Fu, S., Tsimberidou, A.M., Piha-Paul, S.A., Wheler, J.J., Zinner, R.G., Naing, A., Hong, D.S., Karp, D.D., Cabrilo, G., Kopetz, E.S., Subbiah, V., Luthra, R., Kee, B.K., Eng, C., Morris, V.K., Karlin-Neumann, G.A., Meric-Bernstam, F.

Volltext

A Phase I Dose-Escalation Study of emd 1214063, an Oral Selective CMET Inhibitor, in Patients with Advanced Solid Tumors von Naing, A., Falchook, G.S., Fu, S., Amin, H.M., Piha-Paul, S.A., Hong, D.S., Tsimberidou, A.M., Wheler, J.J., Janku, F., Klevesath, M.B., Jego, V., Johne, A, Kurzrock, R.

Volltext

L6.5 Personalized Medicine: An Update on 1,985 Patients with Advanced Cancer at Md Anderson Cancer Center von Tsimberidou, A.M., Hong, D.S., Wheler, J.J., Ye, Y., Fu, S., Piha-Paul, S.A., Naing, A., Falchook, G.S., Janku, F., Luthra, R., Wen, S., Kurzrock, R.

Volltext